

PRODUCT INFORMATION



A8SGLP-1 (trifluoroacetate salt)

Item No. 41264

CAS Registry No.: 753024-08-7

Formal Name: L-histidyl-L-seryl-L- α -glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L- α -aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L- α -glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-L-lysyl-L- α -glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl-glycinamide, trifluoroacetate salt

H—His—Ser—Glu—Gly—Thr—Phe—Thr—Ser—Asp—Val—
Ser—Ser—Tyr—Leu—Glu—Gly—Gln—Ala—Ala—Lys—
Glu—Phe—Ile—Ala—Trp—Leu—Val—Lys—Gly—Arg—

Peptide Sequence: HSEGTFTSDVSSYLEGQAAKEFIAWLVKGRG-NH₂

MF: C₁₅₁H₂₂₉N₄₁O₄₇ • XCF₃COOH

FW: 3,370.7

Purity: \geq 98%

Supplied as: A solid

Storage: -20°C

Stability: \geq 4 years

Gly—NH₂

• XCF₃COOH

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

A8SGLP-1 (trifluoroacetate salt) is supplied as a solid. A stock solution may be made by dissolving the A8SGLP-1 (trifluoroacetate salt) in the solvent of choice, which should be purged with an inert gas. A8SGLP-1 (trifluoroacetate salt) is soluble (\geq 10 mg/ml) in ethanol and sparingly soluble (1-10 mg/ml) in DMSO.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of A8SGLP-1 (trifluoroacetate salt) can be prepared by directly dissolving the solid in aqueous buffers. A8SGLP-1 (trifluoroacetate salt) is sparingly soluble in PBS (pH 7.2). We do not recommend storing the aqueous solution for more than one day.

Description

A8SGLP-1 is a peptide agonist of glucagon-like peptide 1 receptor (GLP-1R) and a derivative of GLP-1 (7-36) amide (Item No. 15069).¹ It induces cAMP accumulation in RIN T3 rat pancreatic insulinoma cells (EC₅₀ = 15 nM). Oral administration of lyophilized *L. lactis* expressing A8SGLP-1 reduces blood levels of glucose in the oral glucose tolerance test (OGTT), serum levels of Il-1 β , Il-6, and Tnf- α , and fat mass in diabetic db/db mice.²

References

1. Sarrauste de Menthère, C., Chavanieu, A., Grassy, G., *et al.* Structural requirements of the N-terminal region of GLP-1-[7-37]-NH₂ for receptor interaction and cAMP production. *Eur. J. Med. Chem.* **39**(6), 473-480 (2004).
2. Zhang, H., Dong, M., Yuan, S., *et al.* Oral glucagon-like peptide 1 analogue ameliorates glucose intolerance in db/db mice. *Biotechnol. Lett.* **44**(10), 1149-1162 (2022).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/12/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM